Embed Size (px)
Citation preview
April 18, 2018 @ 1:00pm Company Presentation
© Copyright 2019 – CONFIDENTIAL 2
Safe Harbor
This information does not constitute an offer to sell or a solicitationof an offer to buy securities or assets of MariMed Inc. Allinformation presented herein with respect to the existing businessand the historical operating results of MariMed Inc. And estimatesand projections as to future operations are based on materialsprepared by the management of MariMed Inc. and involvesignificant elements of subjective judgment and analysis which mayor may not be correct. While the information provided herein isbelieved to be accurate and reliable, MariMed Inc. makes norepresentations or warranties, expressed or implied, as to theaccuracy or completeness of such information. In furnishing thisinformation, MariMed Inc. reserves the right to amend or replacesome or all of the information herein at any time and undertakes noobligation to provide the recipient with access to any additionalinformation. Nothing contained herein is or should be relied upon asa promise or representation as to the future.
This information includes certain statements, estimates andprojections provided by MariMed Inc. with respect to its anticipatedfuture performance. Such statements, estimates and projectionsconstitute forward-looking statements within the meaning of thefederal securities laws. These forward-looking statements aresubject to known and unknown risks, uncertainties and otherfactors, which may cause actual results to be materially differentfrom those contemplated by the forward-looking statements.MariMed Inc. undertakes no obligation to publicly update or reviseany forward-looking statements, whether as a result of newinformation, future events or otherwise. The recipient of thisinformation is cautioned not to place undue reliance on forward-looking statements. No representations or warranties are made asto the accuracy of such forward-looking statements or whether anyof the projections included herein will be realized.
“Cannabis has the power to transform
human health and wellness.”
Bob Fireman | CEO MariMed Inc.
© Copyright 2019 – CONFIDENTIAL 4
About MariMed
Who We Are
▪ Publicly-traded, vertically integrated multi-state cannabis operator
▪ Industry leader in development and management of seed-to-sale cannabis facilities
▪ Leader in cannabis innovation and technology
▪ 13 cannabis licenses for cultivation, production, and dispensaries in multiple states
▪ Manage over 300,000 square feet of premier cannabis facilities
▪ Broad portfolio of trusted brands of precision-dosed, high-quality cannabis products
▪ Support research and doctor education to improve patient outcomes
▪ Consolidate and expand operational footprint in US and abroad
▪ Build brand portfolio with novel and innovative offerings
▪ Expand new presence in hemp-derived CBD market with premium materials and products
▪ Support advancement of research and innovation in cannabis products and therapies
What We Do
Where We’re Going
© Copyright 2019 – CONFIDENTIAL 5
Growing Cannabis Platform
Vertically integrated, multi-state cannabis and
hemp operator
MRMD
Development, licensing, and
management of seed-to-sale
cannabis operations
Seed-to-Sale
Broad portfolio of trusted brands of precision-dosed,
high-quality cannabis products
Brand
Software for customer loyalty
and brand targeting
CRM Platform
Enterprise for supply, brands, and
distribution of hemp-derived CBD
MariMedHemp
Support research and physician
education, supported by
Scientific Advisory Board
Research and Education
© Copyright 2019 – CONFIDENTIAL 6
Leadership Team
OTCQB: MRMD
▪ Specialist in state-of-the-art cannabis facility design and cultivation system management
▪ Specific expertise in agriculture and hydroponics
▪ Drives next generation cultivation processes to maintain industry edge
TIM SHAWCOO
▪ Successful entrepreneur, attorney, and investor with diversified portfolio
▪ Early pioneer and visionary in evolving legal medical cannabis industry
ROBERT FIREMANFounder & CEO
▪ Operational experience from range of real estate and healthcare businesses
▪ Maintains financial operations, cannabis tax reporting, and code requirements that exceed regulator expectations
JON LEVINEFounder & CFO
▪ Leads corporate strategy, M&A, and investments
▪ Previously Wall Street’s only full-time cannabis analyst
▪ Founder of EFW Partners, an industry venture fund, and was Partner at Crosslink Capital
CHARLES FINNIECSO
© Copyright 2019 – CONFIDENTIAL 7
Product Team
▪ Skilled in a hybrid of education and marketing experience with a robust focus on curriculum development
▪ Spearheads brand development, strategic planning, event planning and marketing campaigns branded products and licensed products
▪ Serial entrepreneur with consumer and commercial brand building and product development experience. Operational and marketing expertise including international manufacturing and distribution
▪ James co-founded CannaKorp, makers of the Wisp vaporizer; acquired in 2019
▪ Cannabis product development expert with a proven track record of global sales and business development
▪ Ryan co-founded Betty’s Eddies which MariMed acquired in 2017
RYAN CRANDALLSVP Sales & Chief Product Officer
▪ Expert in extraction methods and product manufacturing
▪ Responsible for production planning and manufacturing at all of MariMed’s operations including training and troubleshooting for all licensees
JAMES WINOKURSVP & General Manager
AMBER STAFFAVP Marketing
RYAN BANKSHead of Production
© Copyright 2019 – CONFIDENTIAL 8
Expanding National Footprint
PENNSYLVANIA
MARYLAND
MAINE NEW JERSEYMICHIGAN
ILLINOISNEVADA DELAWARERHODE ISLAND MASSACHUSETTS
KENTUCKY
Near-Term Domestic Expansion
3 licenses (vertical integration)Wholesale to all dispensaries
Cultivation, production 2 dispensariesMRMD brands distribution
Slater CenterMRMD team membersMRMD brands distribution
2 Licensed dispensariesMRMD brands distribution
1 license cultivationMRMD brands distribution
Brand distributed to top dispensary
33.5% investmentin GenCanna
HEMP Cannabis
© Copyright 2019 – CONFIDENTIAL 9
Proven Seed-to-Sale Experience
OTCQB: MRMD
Select examples:
Rhode Island Maryland
Massachusetts Delaware
20K+ medical patients1K+ visitors/day$2.8M/month current run
rate
180K sf cultivation and production facility
Wholesale provider to 102 dispensaries in Maryland
70K sf state of the art cultivation, production, and distribution facility
1 dispensary open Q2 20192 more pending
2 of 4 dispensaries in state47K sf seed-to-sale facility and 5K sf dispensary $1M+/month revenues6,000+ patients
© Copyright 2019 – CONFIDENTIAL 10
International Expansion
Note: Pending minority investments
LITHUANIA SPAIN PORTUGAL URUGUAY
EUROPE FUTURE EXPANSION
HEMP Cannabis
SOUTH AMERICA FUTURE EXPANSIONEUROPEAN EXPANSION
© Copyright 2019 – CONFIDENTIAL 11
Our Brands
Expanding brand development and distribution
Authentic strains & various concentrates
shatter, wax, vape, dabs, rosin
Strips, mints,powderedtinctures
Precision dosing in a gel form to mix in
beverages or direct ingestion
Novel Delivery #1 Edible in IL 3rd Party ValidatedNational Distribution
Rights
Fruit chews, and popcorn
© Copyright 2019 – CONFIDENTIAL 12
Adding Brand Partnerships
Experts in cannabis formulations for specific effects
Pure genetics, >10 years trials
in Israel; strains, tinctures, sublingual; MRMD has exclusive
distribution in 5 states
Launched in MD Doctor Formulated Effect Based Research Backed
Novel concentrate delivery through clean, convenient
ceramic
Doctor developed medical cannabis
tincture formulations
© Copyright 2019 – CONFIDENTIAL 13
MariMed Hemp
▪ MariMed (MM) made significant investment in GenCanna, (GC) a Kentucky-based vertically integrated hemp producer of GMP-compliant CBD oils and isolates, to facilitate rapid expansion of GC hemp acreage and processing to be one of largest CBD derived from hemp in the USA.
▪ MariMed Hemp (MMH), subsidiary of MM formed to optimize its strategic investment by:
oDeveloping Brands of CBD health and beauty products with 100% GMP compliant chain of custody from seed to sale
oProducts to have superior formulations for best bio-availability utilizing MM’s years of technology experience with cannabinoids
© Copyright 2019 – CONFIDENTIAL 14
Hemp-Derived CBD Market
Sources: (1) New Frontiers Data 2018 market report; MariMed projections; (2) Brightfield Group
CBD revenues to grow fast as US market expands
Legal CBD sales by product type, US Market ($USD Millions)1
190 180 340550 625 680 740 805
177264
352
450
548647
963
1,433
2,132
240
313
407
516
647
940
1,365
1,982
80594998
2014
3,538
20252015
1,197
131
2016 2017
260
2024
30
20232018
108
2019
845
20222020
2,583
2021
178367
129
534
1,6141,919
4,919
Pharmaceutical
Marijuana-Derived
Hemp-Derived
Product type
Global market to exceed
$22B by 2025 2
Estimated
2
© Copyright 2019 – CONFIDENTIAL 15
FloranceTM Hemp and CBD Products
Citrus Hemp CBD
LozengesEdible Honey
Flowers Hemp CBD
Paste
CBD Free 5 different types 3 versions 3 versions
Hemp seed oil
(CBD free)Hemp CBD Drops
1000
© Copyright 2019 – CONFIDENTIAL 16
Our Strategy
1CONSOLIDATION & EXPANSION OF FOOTPRINT
Continue consolidation and expansion as an emerging
multi-state operator
INCREASE REVENUES FROM HEMP-
DERIVED CBD MARKET
Leverage early entry into market
2
3
BUILD BRAND PORTFOLIO
Continue to expand portfolio of leading brands
© Copyright 2019 – CONFIDENTIAL 17
Pro Forma Revenues...
…once consolidation is completed
Source: MariMed Inc. estimates
$43.5
$92.6
$216.6
$330.1
20212018 2019 2020
Pro forma (consolidated) revenue estimates, MariMed Inc. ($USD Million)
Notes:1. Revenue reflects consolidated operations effective Jan. 1, 2018 (consolidations will be completed
before 2020).2. Estimates do not include 33% of GenCanna EBITDA (to be reported by MRMD as Equity Income).
To learn more, please visit
www.MariMedAdvisors.com
MariMed, Inc.10 Oceana Way
Norwood, MA 02062
ROBERT N. FIREMANChief Executive Officer
Direct: [email protected]
CHARLES H. FINNIEChief Strategy Officer
Direct: [email protected]
OTCQB: MRMD
Thank you for your time…
…we invite your questions and reactions
